TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03288155

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa
Description: Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
Study: NCT01984931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)
Description: Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide hydrochloride monohydrate
Study: NCT02157740

Intervention type: DEVICE
Intervention: Residents of nursing homes with telemedicine after implementation of telemedicine
Study: NCT01968434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: protective cough syrup
Description: The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbocisteine cough syrup
Description: Mucolytic
Study: NCT02276495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACB Control - 20 ml saline injection for ACB
Description: Adductor Canal Block Control (20 ml saline injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
Description: Adductor Canal Block Study (20 ml 0.5% Ropivacaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
Description: Adductor Canal Block Study (20 ml 0.5% Ropivacaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Description: 100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Description: 100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)
Study: NCT06664593

Intervention type: OTHER
Intervention: integrated perinatal mental health pathway
Description: This observational study examines whether assessing psychosocial risk factors and screening for depression and anxiety at different time points during the perinatal period, using a stepped protocol, helps to more quickly detect women with depressive and anxiety symptoms.
Study: NCT03246529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040 1.25 mg/kg + G-CSF
Description: Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo +G-CSF
Description: Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
Study: NCT05166005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
Study: NCT00660010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron (leuprolide acetate)
Description: Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
Study: NCT03864614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217
Study: NCT04133831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Survival
Description: The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\].

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Survival
Description: The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\].

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Survival
Description: The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\].

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival
Description: The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival
Description: The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
Study: NCT01184352

Intervention type: DEVICE
Intervention: TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter
Description: Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
Study: NCT00568308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: 160mg subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo
Study: NCT00653224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine dihydrochloride
Description: 5 mg daily (oral tablet) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0 mg daily (matching oral tablet) for 14 days
Study: NCT04771741

Intervention type: DRUG
Intervention: Acetominophen
Description: 1,000 mg every 6 hours

Intervention type: DRUG
Intervention: Toradol
Description: 10 mg every 6 hours, days 0-3

Intervention type: DRUG
Intervention: Meloxicam
Description: 15 mg once daily, beginning post-op day 4

Intervention type: DRUG
Intervention: Cyclobenzaprine
Description: 10 mg every 8 hours

Intervention type: DRUG
Intervention: Lyrica
Description: 75 mg every 12 hours
Study: NCT04318210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Study: NCT03556631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: live combined Bifidobacterium and Lactobacillus Tablets
Description: take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: live combined Bifidobacterium and Lactobacillus Tablets
Description: take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
Study: NCT02573324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Description: Intravenous (IV) Infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-414
Description: IV Infusion (IV)
Study: NCT00752505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esreboxetine
Description: Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esreboxetine
Description: Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
Study: NCT04427956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal crosslinking: CXL (UVA 9mW/cm2)
Description: CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal crosslinking: CXL (UVA 9mW/cm2)
Description: CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal crosslinking: CXL (UVA 9mW/cm2)
Description: CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic riboflavin
Description: CXL protocol with isotonic riboflavin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic riboflavin
Description: CXL protocol with hypotonic riboflavin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iontophoresis
Description: CXL protocol with iontophoresis and ricrolin
Study: NCT03772548

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: We will examine acute (\<4 weeks post SCI) to chronic (\>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
Study: NCT03601923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial.
Study: NCT00971971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis
Description: dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Standard SLED
Study: NCT01306552

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Student-Intervention only group
Description: One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-component Intervention
Description: One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)
Study: NCT01010984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC beads loaded with Doxorubicin
Description: During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
Study: NCT00608829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE TAG® Thoracic Endoprosthesis
Description: Implant
Study: NCT02192684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45 mg daily Insulin sensitizing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Compare with pioglitazone
Study: NCT01330940

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange soda
Description: 32 ounces per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange soda
Description: 32 ounces per day
Study: NCT00129519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod 5% cream
Description: Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
Study: NCT03526224

Intervention type: DRUG
Intervention: Dimethyl Fumarate
Description: Individuals with MS treated with dimethyl fumarate (Tecfidera)

Intervention type: DRUG
Intervention: Teriflunomide
Description: Individuals with MS treated with teriflunomide (Aubagio)
Study: NCT00927446

Intervention type: PROCEDURE
Intervention: Endoscopy screening with narrow band imaging
Description: Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
Study: NCT01312545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DP
Description: intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medpor
Description: commercial porous polyethylene
Study: NCT01479036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and epirubicin
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and epirubicin plus endostatin
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
Study: NCT00000435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dnaJ peptide
Description: dnaJP1 was taken in pill form at 25mg/day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: None-placebo
Description: placebo was taken in pill form at 25mg/day for 6 months
Study: NCT02497664

Intervention type: OTHER
Group type: OTHER
Intervention: Active Breathing Control
Study: NCT01917045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil (R30730, brand name Sufenta)
Description: sufentanil 1ug/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil (R30730, brand name Sufenta)
Description: sufentanil 1ug/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil (R30730, brand name Sufenta) + Morphine
Description: sufentanil 0.5ug/ml+morphine 0.25mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil (R30730, brand name Sufenta) + Morphine
Description: sufentanil 0.5ug/ml+morphine 0.25mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine 0. 5mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine 0. 5mg/ml
Study: NCT02096835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous electrical acupoint stimulation
Description: The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham transcutaneous electrical acupoint stimulation
Description: The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tropisetron
Description: will be given at the start of skin closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: will be given after induction

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone
Description: will be given after induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: will be given after induction
Study: NCT03650426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee with onlay patellar resurfacing technique
Description: The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee with inlay patellar resurfacing technique
Description: The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
Study: NCT01903694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib + Pravastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Study: NCT02284828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study: NCT02261818

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meetings with peer mentors
Description: Peer mentors provide social support to address depressive symptoms
Study: NCT04313153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: intravenous or subcutaneous solution
Study: NCT05104398

Intervention type: DEVICE
Intervention: Efferon CT
Description: extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
Study: NCT02676206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical music
Description: Classical music will be played over the headphones
Study: NCT03129347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
Study: NCT04749264

Intervention type: BEHAVIORAL
Intervention: Mindfulness meditation retreat
Description: 6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.